To our knowledge, this is the first study providing IL-6 characteristics in COVID-19 critically ill patients managed in Tunisia and determining fatal cut-off, which may be helpful for determining treatment regimens and management in severe cases. This evidence concerns the gene IL6 and COVID-19.